Maternal serum alpha-fetoprotein (MSAFP) concentration typically rises during pregnancy and is routinely estimated during the second trimester as a part of a screening protocol for fetal neural tube defects and Down syndrome. By measuring the MSAFP levels, healthcare professionals can directly assess the chromosomal or congenital factors, facilitating rapid and effective intervention.